| PAPAJIK, Tomas, Zuzana PIKALOVA, Ludek RAIDA, Ivana SKOUMALOVA, Jana VONDRAKOVA, Edgar FABER, Vit PROCHAZKA, Zuzana KUBOVA, Ladislava KUCEROVA, Tomas PAVLIK, Ladislav DUŠEK and Karel INDRAK. RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. BIOMEDICAL PAPERS-OLOMOUC. 2009, vol. 153, No 3, p. 211-214. ISSN 1213-8118. |
Other formats:
BibTeX
LaTeX
RIS
@article{869329,
author = {Papajik, Tomas and Pikalova, Zuzana and Raida, Ludek and Skoumalova, Ivana and Vondrakova, Jana and Faber, Edgar and Prochazka, Vit and Kubova, Zuzana and Kucerova, Ladislava and Pavlik, Tomas and Dušek, Ladislav and Indrak, Karel},
article_number = {3},
keywords = {Diffuse large B-cell lymphoma; Rituximab; Stem cell transplantation},
language = {eng},
issn = {1213-8118},
journal = {BIOMEDICAL PAPERS-OLOMOUC},
title = {RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION},
volume = {153},
year = {2009}
}
TY - JOUR
ID - 869329
AU - Papajik, Tomas - Pikalova, Zuzana - Raida, Ludek - Skoumalova, Ivana - Vondrakova, Jana - Faber, Edgar - Prochazka, Vit - Kubova, Zuzana - Kucerova, Ladislava - Pavlik, Tomas - Dušek, Ladislav - Indrak, Karel
PY - 2009
TI - RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION
JF - BIOMEDICAL PAPERS-OLOMOUC
VL - 153
IS - 3
SP - 211-214
EP - 211-214
SN - 12138118
KW - Diffuse large B-cell lymphoma
KW - Rituximab
KW - Stem cell transplantation
N2 - The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation in 69 patients with poor-risk, diffuse large B cell lymphoma. A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x10(6)/kg in the nonR group and 7.81x10(6)/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was found in the non-R group (98.1x10(4)/kg) compared to the R group (76.6x10(4)/kg; p = 0.068). The non-R patients had a much higher median number of BFU-E (90.9x10(4)/kg) than the R patients (31.3x10(4)/kg; p = 0.001). Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.179).
ER -
PAPAJIK, Tomas, Zuzana PIKALOVA, Ludek RAIDA, Ivana SKOUMALOVA, Jana VONDRAKOVA, Edgar FABER, Vit PROCHAZKA, Zuzana KUBOVA, Ladislava KUCEROVA, Tomas PAVLIK, Ladislav DUŠEK and Karel INDRAK. RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION. \textit{BIOMEDICAL PAPERS-OLOMOUC}. 2009, vol.~153, No~3, p.~211-214. ISSN~1213-8118.
|
